Pharmaceutical Companies

The U.S. Food and Drug Administration (FDA) recently approves an updated label for UNLOXCYT based on long-term follow-up data from the pivotal CK-301-101 clinical trial.

This collaboration delivers crucial funding to Agenus while simultaneously securing sustained biologics manufacturing capacity within the United States.

Caldera raised USD75 million in a Series A financing round led by Atlas Venture, LAV, and venBio, followed by an additional USD37.5 million in a Series A-1 round led by Omega Funds.

The site will house the company’s signature technology: the fully automated Cell Shuttle production platform alongside Cell Q quality control systems.

The companies unveiled their partnership at the 2026 J.P. Morgan Healthcare Conference, which took place from January 12 to 15 in San Francisco.

This new 35,000 square foot, purpose-built site represents Novartis’s fourth dedicated RLT facility.

Nimbus will leverage its specialized expertise in computational chemistry and structure-based drug design to discover a small molecule drug candidate.

The NMPA based its decision on compelling evidence from the TRIDENT-1 study, a pivotal Phase I/II clinical trial that demonstrated the drug’s effectiveness over time.

Amgen’s latest acquisition is centered on Dark Blue’s lead candidate, DBT 3757, which specifically treats acute myeloid leukemia that affects bone marrow and blood cells.

Sanofi will leverage Earendil’s artificial intelligence (AI)-powered drug discovery platform to support the design and development of multiple new therapeutic assets.